Tim Moss
Head of Finance and Governance
Tim Moss is an accountant who oversees the finances and governance for GAFFI and GAFFi UK. Tim qualified as a chartered accountant with Pannell Kerr Forster in London in 1990 and has over 30 years experience having held senior financial positions with a number of private and public companies in financial services, utilities, food product development, communications and telecoms sectors. He has been based in Geneva, Switzerland, since May 2006.
He has wide ranging commercial experience, developing strategies, financial reporting, audit and corporate governance to meet statutory and stakeholder expectations. Considerable experience managing, developing and implementing processes designed for rapidly expanding enterprises including budgeting¸ cash flow and fund raising.
Nkechi (Mbanefo) Azie MD MBA FIDSA
Nkechi (Mbanefo) Azie MD MBA FIDSA is a highly accomplished pharmaceutical executive. Dr. Azie is widely recognized as an expert in the field of infectious diseases with breadth of experience in translational medicine, drug development, medical affairs, product launches and pharmacovigilance. She has held key leadership roles in the clinical development of major antifungals and antibiotics for Astellas, Pfizer, The Medicines Company and, most recently, Scynexis. She has broad experience that also covers vaccines, immunology, neurology, gastrointestinal disease, and women’s health. Dr. Azie has extensive experience interacting with the FDA and other global regulatory agencies to deliver safe and effective products at the global level. She has successfully led product Lifecycle management strategies to optimize product value to patients, payers, and companies. Dr. Azie, a native of Nigeria, obtained her medical degree at the University of Nigeria. She did her medical/infectious diseases residency training at Indiana University, and obtained an MBA from Notre Dame University. Currently, she is the Global Chief Medical Officer for SymBio Pharmaceuticals
Dr. Sulaiman Lakoh
Lecturer, Division of Infectious Disease, Department of Medicine, College of Medicine and Allied Health Sciences, University of Sierra Leone.
Link
Nelesh P. Govaender
Head, Centre Healthcare-Associated Infections, AMR and Mycoses, National Institute for Communicable Diseases, Johannesburg, South Africa.
Link
Dr Anna Rozaliyani
Head of Dept. of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, - Chairperson of Indonesian Society of Respirology (ISR), Jakarta Chapter - Coordinator of Indonesia Pulmonary Mycoses & Fungal Culture Collection (IPMC & FCC), Jakarta.
Link
Dr. Sherif M Zaki
Associate Professor of Medical Mycology , Mycology Unit, Department of Microbiology, Faculty of Science, Ain Shams University, Cairo, Egypt.
Link
Eduardo G. Arathoon
Medical Director, Asociacion de Salud Integral (ASI), Guatemala City, Guatemala
Link
David Allmond
David Allmond is a passionate, life sciences professional, with a particular interest in strategy development. He has an impressive multi-national leadership background and in recent years has focused his career on clinical diagnostics in infectious diseases and commercialization of medicines to tackle severely underserved, debilitating cancers and orphan diseases. His most recent post was Chief Executive Officer for Novacyt Group, an international clinical diagnostics company.
Prior to this David has held a number of senior positions across the pharmaceutical industry:
Chief Business Officer for Amryt Pharma, a global pharmaceutical company focused on developing and delivering innovative treatments to improve the lives of people with rare and orphan diseases.
President EMEA for Aegerion Pharmaceuticals where he was responsible for the EMEA P&L and was tasked with turning the business around to ensure it was fit to deliver profitable growth, after a challenging entry into the region.
General manager Celgene UK, responsible for setting up Celgene’s UK and Ireland operating company and subsequently Vice President EMEA Marketing and Market Access followed by his move to the US to assume the role of Corporate Vice President, Global Marketing for Celgene, where he played a pivotal role in defining brand and portfolio strategy.
David spent nearly 7 years on the board of Myeloma UK, a highly progressive patient group, supporting patients with Multiple Myeloma. He holds a Bachelor of Science degree in Microbiology from Imperial College, London.
David S. Perlin, Ph.D.
Dr. David S. Perlin is a highly accomplished biomedical researcher and chief executive who is well recognized for his innovative and entrepreneurial leadership in the biomedical sciences. He is the inaugural Chief Scientific Officer and EVP for the Hackensack Meridian Center for Discovery and Innovation (CDI), which rapidly translates innovations in science to improve outcomes for patients with cancer, infectious diseases, and other acute and chronic disorders. Dr. Perlin has been engaged for >30 years in developing molecular insights and technologies to detect, combat and prevent deadly infections. He is an expert in drug discovery and drug resistance mechanisms, and he has helped develop novel therapeutics and diagnostics against high-threat bacteria, viruses, and fungi. He has published more than 340 papers and book chapters and has co-authored two books. His laboratory is supported by multiple grants from the NIH, Pharma and biopharma sectors. Dr. Perlin has served on advisory boards for the NIH, Bill & Melinda Gates Foundation, Aaron Diamond AIDS Research Center, and numerous Pharma, biotech and diagnostic companies. Under Dr. Perlin’s leadership, CDI was named in 2020 the top Business Incubator in New Jersey and was further honored with a “Medical Technology Pioneer Health Care Heroes” award for their COVID-19 response. Dr. Perlin is a Fellow of the American Academy of Microbiology (2018) and the New York Academy of Sciences (2006). He was named by RO1 a top 10 influencer in healthcare in New Jersey in 2019 and 2020; Outstanding Scientist in New Jersey by the Edward J. Ill Excellence in Medicine Awards in 2020, 2021; a top 25 National Innovator by Modern Healthcare in 2021, and in 2022 a top 25 Notable Health Care Leader by Crain’s New York Business. Finally, he received the 2023 Sol J. Barer award for Vision, Innovation and Leadership.
Skhumbuzo Ngozwana
Dr Skhumbuzo Ngozwana is CEO of Kiara Health, a South African based, Africa-focused healthcare company. He is an international expert on the African Pharmaceutical industry and has worked in both private and global public health organizations. He consulted to the World Health Organization (WHO), United Nations Industrial Development Organization (UNIDO) and the United States Pharmacopeia Convention (USP). He co-authored the Pharmaceutical Manufacturing Plan for Africa. The plan was the output of the extensive research and analytical work he conducted on the African pharmaceutical industry. He co-authored the Ethiopian Pharmaceutical Sector Strategy and Action Plan and the pharmaceutical sector strategies of several countries. He consulted for USP on their Africa strategy and authored a USP Thought Leadership Paper titled, The Next Frontiers for the Public Health Medicines Market: Rethinking Priorities for Improved Access to Quality-Assured Medicines for Universal Access. He is passionate about the development of the local pharmaceutical and medtech sector in Africa as a way to achieve health security and has written and spoken on the topic at leading local and international conferences.